Clinical trials for Pegylated interferon

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44341 clinical trials with a EudraCT protocol, of which 7370 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (179)
Paediatric studies in scope of Art45 of the Paediatric Regulation (2)

179 result(s) found for: Pegylated interferon. Displaying page 8 of 9.

EudraCT Number: 2012-003738-18

Sponsor Protocol Number: M13-862

Start Date*: 2013-04-26

Sponsor Name:AbbVie Deutschland GmbH & Co. KG

Full Title: A Randomized, Open-Labeled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with Ribavirin Compared to Telaprevir Co-administered with Pegylated In...

Medical condition: Chronic Hepatitis C Infection

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10021881 - Infections and infestations	10008912	Chronic hepatitis C	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: HU (Completed) FI (Completed) SK (Completed) PL (Completed)

Trial results: View results

EudraCT Number: 2006-002696-40

Sponsor Protocol Number: ACH171-002

Start Date*: 2006-10-12

Sponsor Name:Achillion Pharmaceuticals, Inc.

Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Multiple Doses of ACH-0137171 in Subjects w...

Medical condition: Chronic Hepatitis C Infection

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.1		10008912	Chronic hepatitis C	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: DE (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2011-004810-41

Sponsor Protocol Number: MV28073

Start Date*: 2012-04-18

Sponsor Name:F. Hoffmann-La Roche Ltd

Full Title: An international, multicenter, open-label study evaluating sustained virological response and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in...

Medical condition: Genotype 1 CHC virus infection

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	16.1	10021881 - Infections and infestations	10008912	Chronic hepatitis C	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: AT (Completed) HU (Completed) ES (Completed) PL (Completed) DE (Completed)

Trial results: View results

EudraCT Number: 2012-003754-84

Sponsor Protocol Number: M13-774

Start Date*: 2013-04-24

Sponsor Name:AbbVie Deutschland GmbH & Co. KG

Full Title: A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with and without Ribavirin Compared to Telaprevir Co-administered with Pe...

Medical condition: Chronic Hepatitis C Infection

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10021881 - Infections and infestations	10008912	Chronic hepatitis C	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: HU (Completed) FI (Completed) SK (Completed) PL (Completed)

Trial results: View results

EudraCT Number: 2010-019367-11

Sponsor Protocol Number: ANRS HB 06

Start Date*: 2010-08-30

Sponsor Name:ANRS

Full Title: ANRS HB 06 PEGAN Essai de phase III, randomisé, multicentrique, sans insu, évaluant à S96 la perte de l’Ag HBs suite à un traitement de 48 semaines par l’interféron pégylé alpha 2a chez des patient...

Medical condition: Cette étude va évaluer la perte de l’Ag HBs lors d’un traitement par l’interféron pégylé alpha-2a pendant 48 semaines chez des patients ayant une hépatite B chronique (AgHBe négatif), et une charge...

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	12.1		10008910	Chronic hepatitis B	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Ongoing)

Trial results: View results

EudraCT Number: 2011-005989-38	Sponsor Protocol Number:	Start Date*: 2012-11-01
Sponsor Name:Norwegian University of Science and Technology
Full Title: A SAFETY AND EFFICACY STUDY OF ADDING LOW DOSE PEGYLATED IFN-ΑLPHA 2B TO STANDARD DOSE DASATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA
Medical condition: Chronic myeloid leukemia
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: NO (Completed) FI (Completed) SE (Ongoing) DK (Completed)
Trial results: (No results available)

EudraCT Number: 2009-010273-20

Sponsor Protocol Number: 18081

Start Date*: 2012-11-28

Sponsor Name:European organisation for research and treatment of Cancer

Full Title: Adjuvant peginterferon alfa-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group.

Medical condition: Ulcerated primary cutaneous melanoma >1mm (T2b-4bN0M0)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	18.0	100000004864	10027156	Skin melanomas (excl ocular)	HLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed) GB (Completed) DE (Completed) FR (Completed) AT (Completed) IT (Completed) DK (Completed) ES (Completed) NL (Completed) PT (Completed) PL (Completed)

Trial results: View results

EudraCT Number: 2011-005055-14

Sponsor Protocol Number: P7977-1231

Start Date*: 2012-03-19

Sponsor Name:Gilead Sciences Inc.

Full Title: A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks...

Medical condition: Chronic Genotype 2 or 3 HCV Infection

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10022891 - Investigations	10019752	Hepatitis C virus (HCV)	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SE (Completed) EE (Completed) IT (Completed) ES (Completed) NL (Completed)

Trial results: View results

EudraCT Number: 2006-006604-11

Sponsor Protocol Number: NV19865

Start Date*: 2007-12-06

Sponsor Name:F. Hoffmann-La Roche Ltd

Full Title: A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) when given in combination with Pegasys...

Medical condition: Chronic hepatitis C

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10008912	Chronic hepatitis C	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: AT (Completed) DE (Completed) FR (Completed) ES (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2011-004653-31

Sponsor Protocol Number: CDEB025A2306

Start Date*: 2012-02-22

Sponsor Name:Novartis Pharma Services AG

Full Title: A multicenter, single-arm trial evaluating the safety and efficacy of DEB025/Alisporivir in combination with pegylated interferon-α2a and ribavirin (peg-IFNα2a/RBV) in protease inhibitor treatment ...

Medical condition: Chronic hepatitis C genotype 1 protease inhibitor (PI) treatment failure

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10021881 - Infections and infestations	10008912	Chronic hepatitis C	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended)

Trial results: View results

EudraCT Number: 2007-001601-16

Sponsor Protocol Number: GS-US-227-0102

Start Date*: 2007-04-13

Sponsor Name:Gilead Sciences Incorporated

Full Title: A Phase IIa, Double-blind, Randomised, Placebo-Controlled Dose Escalation Study to Evalulate the Safety, Tolerability, Pharmacokinetics and Activity of GS-9450, a Caspase Inhibitor, in Subjects wit...

Medical condition: Chronic Hepatitis C

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10008912	Chronic hepatitis C	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: NL (Completed) DE (Completed) FR (Completed)

Trial results: View results

EudraCT Number: 2009-010806-12

Sponsor Protocol Number: COLO400A2430

Start Date*: 2009-07-22

Sponsor Name:Novartis Farmacéutica S.A

Full Title: Estudio multicéntrico, aleatorizado, abierto, controlado para comparar la Respuesta Virológica Sostenida durante el tratamiento con Sandimmun Neoral® o tacrolimus en el mantenimiento de receptores ...

Medical condition: pacientes con trasplante hepático con infección recurrente por Hepatitis C

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10008912	Chronic hepatitis C	LLT
	9.1		10024716	Liver transplantation	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: ES (Completed) BE (Completed) IT (Completed) HU (Completed) FR (Completed) DE (Completed) AT (Completed) GB (Completed)

Trial results: View results

EudraCT Number: 2012-002515-25

Sponsor Protocol Number: LLC-TEL-2012-1

Start Date*: 2012-09-10

Sponsor Name:Luis López Cortes - FISEVI

Full Title: Pharmacokinetic interactions between Telaprevir and not powered Atazanavir with ritonavir in co-infected patients with HIV and HCV genotype 1 in treatment for chronic liver disease by HCV

Medical condition: HIV–HCV co-infected patients

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	10021881 - Infections and infestations	10020161	HIV infection	PT
	14.1	10021881 - Infections and infestations	10065949	HCV coinfection	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2012-005591-33

Sponsor Protocol Number: HIVCOBOC-RGT

Start Date*: 2013-07-29

Sponsor Name:Universitätsklinik f. Innere Medizin III, Medizinische Universität Wien

Full Title: Response-guided triple therapy using boceprevir in combination with PEGIFN/RBV in HIV/HCV coinfected patients

Medical condition: Chronic genotype 1 HCV coinfection in HIV-positive patients.

Disease:	Version	SOC Term	Classification Code	Term	Level
	16.0	10021881 - Infections and infestations	10065949	HCV coinfection	LLT
	16.0	10021881 - Infections and infestations	10020161	HIV infection	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: AT (Completed)

Trial results: View results

EudraCT Number: 2007-001130-13

Sponsor Protocol Number:

Start Date*: 2007-12-05

Sponsor Name:Malmö University Hospital

Full Title: Hepatitis C in a cohort of patients with maintenance therapy for opiate dependence - prevalence, severity and outcome of antiviral therapy

Medical condition: Hepatitis C

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10019744	Hepatitis C	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: SE (Completed)

Trial results: (No results available)

EudraCT Number: 2006-002695-17

Sponsor Protocol Number: DEB-025-HCV-203

Start Date*: 2006-09-21

Sponsor Name:DEBIOPHARM S.A.

Full Title: A multi-centre, randomised, double-blind, placebo-controlled escalating dose ranging phase II study on the efficacy of DEBIO-025 to reduce HCV viral load in combination with PEGASYS 180 g/week i...

Medical condition: treatment na ve patients with chronic hepatitis C

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.1		10019744	Hepatitis C	LLT

Population Age: Elderly

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: View results

EudraCT Number: 2010-018361-33

Sponsor Protocol Number: HCV689-201

Start Date*: 2010-09-10

Sponsor Name:Arrow Therapeutics Ltd. (a member of the AstraZeneca group of companies)

Full Title: A Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AZD7295 in Combination with Pegylated Interferon alpha-2a and Ribavirin in P...

Medical condition: Chronic hepatitis C virus (genotype 1b) infection

Disease:	Version	SOC Term	Classification Code	Term	Level
	12.1		10008912	Chronic hepatitis C	LLT
	12.1		10019744	Hepatitis C	LLT
	12.1		10019751	Hepatitis C virus	LLT
	12.1		10047457	Viral hepatitis C	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: SK (Completed) HU (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2011-000759-18

Sponsor Protocol Number: 5172-003

Start Date*: 2011-07-13

Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA

Full Title: A Randomized, Active-Controlled Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly with Peginterferon ...

Medical condition: Hepatitis C Virus Infection

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10021881 - Infections and infestations	10019744	Hepatitis C	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) BE (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2010-024557-36

Sponsor Protocol Number: VHCRP1007

Start Date*: 2012-05-29

Sponsor Name:The Kirby Institute

Full Title: A phase IV open-label multicentre, international trial of response guided treatment with directly observed pegylated interferon alfa 2b and self-administered ribavirin for patients with chronic HCV...

Medical condition: Chronic Hepatitis C genotype 2 and 3 infection.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	18.0	10021881 - Infections and infestations	10008912	Chronic hepatitis C	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed) BE (Completed) DE (Completed)

Trial results: View results

EudraCT Number: 2007-004993-15

Sponsor Protocol Number: MV21371

Start Date*: 2008-03-07

Sponsor Name:F. Hoffmann-La Roche Ltd

Full Title: A Randomized, Open-Label, Multicenter Study Examining the Effects of 24 Versus 48 Weeks of Combination Therapy with PEGASYS® (Peginterferon alfa-2a 40KD) plus COPEGUS® (Ribavirin) on Sustained Vi...

Medical condition: Chronic hepatitis C

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10008912	Chronic hepatitis C	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: AT (Completed) BE (Completed) DE (Completed)

Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Tue Jun 03 14:36:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA